|
Rosemary Mazanet M.D. Ph.D. age 51 has served as a director since October 2001 and currently serves on the Nominating and Corporate Governance Committee. Dr. Mazanet has served as the Chief Executive Officer of Breakthrough Therapeutics LLC a therapeutic development company since February 2004. She also served as acting Chief Executive Officer of Access Pharmaceuticals (AMEX: AKC) from May 2005 to February 2006. From June 1998 to February 2004 Dr. Mazanet served as Chief Scientific Officer and a General Partner of Oracle Partners L.P. a hedge fund. Prior to joining Oracle Partners Dr. Mazanet served as the Director of Clinical Research at Amgen Inc. a pharmaceutical company. Dr. Mazanet is a member of the Board of Trustees of the University of Pennsylvania School of Medicine. She trained in internal medicine at the Brigham and Women�s Hospital and in oncology at the Dana Farber Cancer Institute both part of the Harvard Medical system where she was a staff physician prior to joining Amgen. Dr. Mazanet holds a B.A. in Biology from the University of Virginia and an M.D. and a Ph.D. from the University of Pennsylvania. | 